Use este identificador para citar ou linkar para este item: https://observatorio.fm.usp.br/handle/OPI/266
Título: Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Autor(es): MORROW, David A.BRAUNWALD, EugeneBONACA, Marc P.AMERISO, Sebastian F.DALBY, Anthony J.FISH, Mary PollyFOX, Keith A. A.LIPKA, Leslie J.LIU, XuanNICOLAU, Jose CarlosOPHUIS, A. J. OudePAOLASSO, ErnestoSCIRICA, Benjamin M.SPINAR, JindrichTHEROUX, PierreWIVIOTT, Stephen D.STRONY, JohnMURPHY, Sabina A.
Parte de: NEW ENGLAND JOURNAL OF MEDICINE, v.366, n.15, p.1404-1413, 2012
Resumo: BACKGROUND Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)
Aparece nas coleções:

Artigos e Materiais de Revistas Científicas - FM/MCP
Departamento de Cardio-Pneumologia - FM/MCP

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor

Artigos e Materiais de Revistas Científicas - LIM/11
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação


Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
art_NICOLAU_Vorapaxar_in_the_Secondary_Prevention_of_Atherothrombotic_Events_2012_eng.pdf
  Restricted Access
publishedVersion (English)2.05 MBAdobe PDFVisualizar/Abrir    Solicitar uma cópia

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.